Moderna Co-Founder Warns AI Cannot Replace Human Clinical Trials Soon
Moderna, Inc. (NASDAQ:MRNA) co-founder and chairman Noubar Afeyan warned that artificial intelligence will not be able to replace human clinical trials in the near future. Speaking at an industry conference in New Delhi, Afeyan urged researchers to remain humble about the limits of human biological knowledge and cautioned against overblown claims that digital simulations could eliminate the need for traditional testing. Shares of Moderna traded up 1.17% at 216.2 USD following the executive's remarks.
While pushing back against expectations of replacing clinical trials entirely, Afeyan noted that AI can still streamline key drug development bottlenecks. Machine learning systems can analyze electronic medical records and molecular data to match suitable patient groups to studies, while also improving cancer screening accuracy by cutting false positives. Reducing research duration and regulatory delays could significantly lower overall pharmaceutical development costs.
Investors and healthcare observers should watch for how regulatory frameworks adapt to autonomous AI tools and biological agents. Afeyan called for strict safety oversight of independent AI agents before commercial deployment, drawing comparisons to drug safety standards established after historical medical crises. Industry leaders continue to monitor AI capabilities like protein structure prediction systems for potential efficiency gains in early-stage scientific research.
Key points
- Moderna, Inc. (NASDAQ:MRNA) chairman Noubar Afeyan warned AI cannot replace clinical trials soon due to human biological complexity.
- Afeyan noted AI can relieve research bottlenecks by analyzing medical records to identify patient cohorts and improving cancer screening accuracy.
- He urged safety regulations for autonomous AI agents similar to strict pharmaceutical testing frameworks.
- Shares of Moderna traded up 1.17% at 216.2 USD following the forum presentation.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Can AI replace human clinical trials in drug development?
Moderna co-founder Noubar Afeyan stated that AI cannot replace clinical trials soon because human biology is too complex for digital simulations to replicate fully.
How can AI assist in pharmaceutical research according to Moderna?
AI can analyze electronic health records and molecular profiles to identify patient groups for trials, improve cancer screening, and reduce research bottlenecks.
What regulation did Moderna's chairman advocate for AI?
Afeyan called for strict regulation of autonomous AI agents, arguing companies must prove their safety before deploying them outside their organizations.